Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · IEX Real-Time Price · USD
-0.01 (-0.05%)
Apr 19, 2024, 4:00 PM EDT - Market closed

Company Description

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally.

The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus.

It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions.

It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health.

Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Myriad Genetics, Inc.
Myriad Genetics logo
Country United States
Founded 1991
IPO Date Oct 5, 1995
Industry Diagnostics & Research
Sector Healthcare
Employees 2,700
CEO Paul J. Diaz

Contact Details

322 North 2200 West
Salt Lake City, Utah 84116
United States
Phone 801-584-3600

Stock Details

Ticker Symbol MYGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000899923
CUSIP Number 62855J104
ISIN Number US62855J1043
Employer ID 87-0494517
SIC Code 2835

Key Executives

Name Position
Paul J. Diaz Chief Executive Officer, President and Director
Dr. Kevin Richard Haas Ph.D. Chief Technology Officer
Mark S. Verratti Chief Commercial Officer
Scott J. Leffler Chief Financial Officer
Samraat S. Raha Chief Operating Officer
Natalie Munk Principal Accounting Officer
Dr. Dale Muzzey Ph.D. Chief Scientific Officer
Matthew Scalo Senior Vice President of Investor Relations
Glenn Farrell Senior Vice President and Chief Marketing Officer
Shereen Solaiman Chief People Officer

Latest SEC Filings

Date Type Title
Apr 17, 2024 ARS Filing
Apr 17, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 17, 2024 DEF 14A Other definitive proxy statements
Apr 10, 2024 144 Filing
Mar 18, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 28, 2024 10-K Annual Report
Feb 27, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals